Journal of medical biochemistry · 2025
Early detection of digestive system cancers: Insights from enzymatic and non-enzymatic tumour markers.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Almohanna Thualfeqar, Auda Furqan Moein, Ali Basim M
Аннотация
BACKGROUND: Digestive system cancer is a silent yet dangerous disease and represents a major cause of death worldwide. Among these cancers, colon cancer is the second leading cause of cancer-related deaths globally. This study aimed to detect malignant cells early by analyzing biochemical indicators associated with the transformation of digestive cancer cells. Tumour markers, primarily proteins associated with malignant cells, may play a role in preventing the spread and progression of the disease.
METHODS: In this study, the tumour markers analyzed included carcinoembryonic antigen (CEA), a-enolase (ENO1), a-fetoprotein (AFP), and calprotectin (CP) to detect digestive system cancer. These markers were measured in serum samples from sixty patients with digestive system cancer (the patient group) and sixty healthy individuals (the control group).
RESULTS: The results revealed highly significant changes (p-value <0.00001) in the levels of CEA (56.698±44.558 ng/mL), ENO1 (51.784±10.395 ng/mL), AFP (116.275±38.956 ng/mL), and CP (287.425±33.181 ng/mL) in the cancerous group compared to the control group, suggesting their potential utility in early diagnosis. Furthermore, significant differences (p-value <0.05) in liver enzymes and body mass index (BMI) provided additional evidence of pathological changes.
CONCLUSIONS: The biomarkers investigated in this study demonstrate promising potential for early diagnosis while contributing to a deeper understanding of the biological mechanisms underlying digestive system cancers.
METHODS: In this study, the tumour markers analyzed included carcinoembryonic antigen (CEA), a-enolase (ENO1), a-fetoprotein (AFP), and calprotectin (CP) to detect digestive system cancer. These markers were measured in serum samples from sixty patients with digestive system cancer (the patient group) and sixty healthy individuals (the control group).
RESULTS: The results revealed highly significant changes (p-value <0.00001) in the levels of CEA (56.698±44.558 ng/mL), ENO1 (51.784±10.395 ng/mL), AFP (116.275±38.956 ng/mL), and CP (287.425±33.181 ng/mL) in the cancerous group compared to the control group, suggesting their potential utility in early diagnosis. Furthermore, significant differences (p-value <0.05) in liver enzymes and body mass index (BMI) provided additional evidence of pathological changes.
CONCLUSIONS: The biomarkers investigated in this study demonstrate promising potential for early diagnosis while contributing to a deeper understanding of the biological mechanisms underlying digestive system cancers.